<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (<z:hpo ids='HP_0100324'>scleroderma</z:hpo>) is an uncommon disease of as-yet-unknown etiology </plain></SENT>
<SENT sid="1" pm="."><plain>The hallmark of <z:hpo ids='HP_0100324'>scleroderma</z:hpo> is proliferation of collagen, particularly types I and III, with associated vascular changes </plain></SENT>
<SENT sid="2" pm="."><plain>Visceral involvement, particularly pulmonary interstitial disease, can lead to significant morbidity and mortality.Specific therapy is unavailable to date, but there has been interest in the use of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> (CSA), because it inhibits interleukin-2 production and affects cytotoxic T cells </plain></SENT>
<SENT sid="3" pm="."><plain>We present a case of a patient with a triad of suspected <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> and Crohn's. disease on CSA therapy for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Despite hematologic response and cutaneous improvement on CSA therapy, this patient developed <z:hpo ids='HP_0006530'>interstitial lung disease</z:hpo> consistent with sclerodermatous lung </plain></SENT>
</text></document>